A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Part of paid clinical trials in Austin, Texas.

Sponsor
IDEAYA Biosciences
Study ID
NCT07503808
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IDE034 — DRUG
    IDE034

Study Details

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Key Dates

Start date
Feb 24, 2026
Status verified
Mar 2026
Primary completion
Jul 30, 2027
Completion
Jul 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1:IDE034 Dose Escalation
    IDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined
  • Experimental: Part 2: IDE034 Dose Expansion
    IDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation

Primary Outcome Measure

Safety and tolerability of IDE034 in Part 1 dose escalation [ Time Frame: 21 days following the first dose of IDE034 ]

Locations (5)

FacilityCityStateZIPSite coordinators
NEXT Texas LLC - AustinAustinTexas78758
Sheena Sahota
737-610-5200
NEXT Texas LLC - HoustonHoustonTexas77054
Jennifer Segar
832-384-7900
NEXT Texas LLC - DallasIrvingTexas75039
Michael Song
972-893-8800
NEXT Texas LLC - San AntonioSan AntonioTexas78229
Dr. Sommerhalder
210-580-9500
NEXT Texas LLC - VirginiaFairfaxVirginia22031
Alexander Spira
703-783-4510

Find similar trials in Austin, TX

Related Studies